# Globus Medical Inc: overview

GMED · NYSE · CIK 1237831 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gmed.md) · [Financials](/companies/gmed/financials.md) · [Filings](/companies/gmed/filings.md) · [Insiders](/companies/gmed/insiders.md)

Latest reported revenue: [$789.6m](/filings/0001628280-26-054450.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-054450).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [626](/filings/0001237831-25-000031.md) | [657 d](/filings/0001628280-26-011209.md) | [598](/filings/0001628280-26-032290.md) | [745](/filings/0001628280-26-054450.md) | [769](/filings/0001237831-25-000031.md) | [826 d](/filings/0001628280-26-011209.md) | [760](/filings/0001628280-26-032290.md) | [790](/filings/0001628280-26-054450.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [7.7%](/filings/0001237831-25-000031.md) | [9.2% d](/filings/0001628280-26-011209.md) | [16.2%](/filings/0001628280-26-032290.md) | [10.2%](/filings/0001628280-26-054450.md) | [17.9%](/filings/0001237831-25-000031.md) | [20.5% d](/filings/0001628280-26-011209.md) | [19.8%](/filings/0001628280-26-032290.md) | [23.1%](/filings/0001628280-26-054450.md) |
| Net margin | % | [8.3%](/filings/0001237831-25-000031.md) | [4.0% d](/filings/0001628280-26-011209.md) | [12.6%](/filings/0001628280-26-032290.md) | [27.2%](/filings/0001628280-26-054450.md) | [15.5%](/filings/0001237831-25-000031.md) | [17.0% d](/filings/0001628280-26-011209.md) | [16.4%](/filings/0001628280-26-032290.md) | [19.2%](/filings/0001628280-26-054450.md) |
| Diluted EPS | $ per share | [0.38](/filings/0001237831-25-000031.md) | not reported | [0.54](/filings/0001628280-26-032290.md) | [1.49](/filings/0001628280-26-054450.md) | [0.88](/filings/0001237831-25-000031.md) | not reported | [0.90](/filings/0001628280-26-032290.md) | [1.10](/filings/0001628280-26-054450.md) |
| Free cash flow | $m | [162 d](/filings/0001237831-25-000031.md) | [193 d](/filings/0001628280-26-011209.md) | [141](/filings/0001628280-26-032290.md) | [31.3 d](/filings/0001628280-26-054450.md) | [214 d](/filings/0001237831-25-000031.md) | [202 d](/filings/0001628280-26-011209.md) | [163](/filings/0001628280-26-032290.md) | [177 d](/filings/0001628280-26-054450.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [958](/filings/0001562762-24-000032.md) | [1,023](/filings/0001562762-25-000026.md) | [1,568](/filings/0001628280-26-011209.md) | [2,519](/filings/0001628280-26-011209.md) | [2,939](/filings/0001628280-26-011209.md) |
| Gross margin | % | [75.0%](/filings/0001562762-24-000032.md) | [74.2%](/filings/0001562762-24-000032.md) | [65.1%](/filings/0001562762-24-000032.md) | not reported | not reported |
| Operating margin | % | [17.9%](/filings/0001562762-24-000032.md) | [22.3%](/filings/0001562762-25-000026.md) | [8.5%](/filings/0001628280-26-011209.md) | [6.6%](/filings/0001628280-26-011209.md) | [16.3%](/filings/0001628280-26-011209.md) |
| Net margin | % | [15.6%](/filings/0001562762-24-000032.md) | [18.6%](/filings/0001562762-25-000026.md) | [7.8%](/filings/0001628280-26-011209.md) | [4.1%](/filings/0001628280-26-011209.md) | [18.3%](/filings/0001628280-26-011209.md) |
| Diluted EPS | $ per share | [1.44](/filings/0001562762-24-000032.md) | [1.85](/filings/0001562762-25-000026.md) | [1.07](/filings/0001628280-26-011209.md) | [0.75](/filings/0001628280-26-011209.md) | [3.92](/filings/0001628280-26-011209.md) |
| Free cash flow | $m | [219](/filings/0001562762-24-000032.md) | [104](/filings/0001562762-25-000026.md) | [165](/filings/0001628280-26-011209.md) | [405](/filings/0001628280-26-011209.md) | [589](/filings/0001628280-26-011209.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gmed/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $853.8m | 10,806,724 |  | Added +309,310 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $656.8m | 7,623,095 |  | Not compared |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $647.9m | 8,200,423 |  | Not compared |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $403.5m | 5,107,532 |  | Added +74,800 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $394.6m | 4,994,385 |  | Added +114,926 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $340.5m | 4,309,771 |  | Reduced −6,883 |
| [KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC](/funds/1021223.md) | 2026-06-30 | $338.1m | 4,279,730 |  | New +4,279,730 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $293.5m | 3,714,029 |  | Added +123,657 |
| [Sculptor Capital LP](/funds/1054587.md) | 2026-06-30 | $237.0m | 3,000,000 |  | Reduced −58,000 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $230.8m | 2,743,850 |  | Added +148,542 |

## Recent filings

[All 753 filings](/companies/gmed/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 17:06 ET | [10-Q](/filings/0001628280-26-054450.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054450 |
| 2026-08-06 | 16:19 ET | [8-K](/filings/0001628280-26-054353.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-054353 |
| 2026-06-04 | 16:11 ET | [8-K](/filings/0001628280-26-040784.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-040784 |
| 2026-05-07 | 17:03 ET | [10-Q](/filings/0001628280-26-032290.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032290 |
| 2026-05-07 | 16:20 ET | [8-K](/filings/0001628280-26-032164.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-032164 |
| 2026-04-24 | 16:04 ET | [DEF 14A](/filings/0001628280-26-027196.md) | Proxy statement, period 2026-06-03 | 0001628280-26-027196 |
| 2026-03-23 | 17:26 ET | [8-K](/filings/0001628280-26-020612.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-020612 |
| 2026-02-24 | 17:08 ET | [10-K](/filings/0001628280-26-011209.md) | Annual report, period 2025-12-31 | 0001628280-26-011209 |
| 2026-02-24 | 16:23 ET | [8-K](/filings/0001628280-26-011124.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-011124 |
| 2026-01-07 | 16:32 ET | [8-K](/filings/0001628280-26-001189.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-001189 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011209.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a376534a-2096-495a-9145-40b41972cf2f)

## About the filer

- CIK: 1237831
- Tickers: GMED
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:47 ET. No prices; not investment advice.